tradingkey.logo

Gain Therapeutics Completes Target Enrollment in Phase 1b GT-02287 Study for Parkinson’s with or without GBA1 Mutation

ReutersJun 30, 2025 8:16 PM

- Gain Therapeutics Inc GANX.O:

  • GAIN THERAPEUTICS ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 1B CLINICAL STUDY EVALUATING GT-02287 IN PEOPLE WITH PARKINSON’S DISEASE WITH OR WITHOUT A GBA1 MUTATION

  • GAIN THERAPEUTICS INC - BIOMARKER ANALYSIS EXPECTED IN 4Q 2025, EARLIER THAN PLANNED

  • GAIN THERAPEUTICS INC - EXTENDS SCREENING FOR PHASE 1B TRIAL THROUGH JULY 31, 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI